Exemestane
Active ingredient: Exemestane
In short: Exemestane is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy . Exemestane is
What is Exemestane used for?
Exemestane is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy
.
Exemestane is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy
.
Exemestane dosage
The recommended dose of exemestane in early and advanced breast cancer is one 25 mg tablet once daily after a meal.
adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane for completion of a total of five consecutive years of adjuvant hormonal therapy.
the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
Concomitant use of strong CYP 3A4 inducers decreases exemestane exposure. For patients receiving exemestane with a strong CYP 3A4 inducer such as rifampicin or phenytoin, the recommended dose of exemestane is 50 mg once daily after a meal
.
How to take Exemestane — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Bone Effects
Advise patients that exemestane lowers the level of estrogen in the body. This may lead to reduction in bone mineral density (BMD) over time. The lower the BMD, the greater the risk of osteoporosis and fracture
.
Other Estrogen-Containing Agents
Advise patients that they should not take estrogen-containing agents while they are taking exemestane as these could interfere with its pharmacologic action
.
Use in Premenopausal Women
Advise patients that exemestane is not for use for the treatment of breast cancer in premenopausal women
.
Embryo-Fetal Toxicity
Advise pregnant women and females of reproductive potential that exposure during pregnancy or within 1 month prior to conception can result in fetal harm. Advise females to inform their healthcare provider of a known or suspected pregnancy
.
Advise females of reproductive potential to use effective contraception while taking exemestane and for 1 month after the last dose
.
Lactation
Advise women not to breastfeed during treatment with exemestane and for 1 month after the last dose
.
Manufactured by:
Eirgen Pharma Ltd. …
Warnings & precautions
Do not take this medicine if: Exemestane tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients.
Reductions in bone mineral density (BMD) over time are seen with exemestane use. Table 1 describes changes in BMD from baseline to 24 months in patients receiving exemestane compared to patients receiving tamoxifen (IES) or placebo (027). Concomitant use of bisphosphonates, vitamin D supplementation, and calcium was not allowed.
IES | 027
BMD | Exemestane
N=29 | Tamoxifen
1
N=38 | Exemestane
N=59 | Placebo
1
N=65
Lumbar spine (%) | -3.1 | -0.2 | -3.5 | -2.4
Femoral neck (%) | -4.2 | -0.3 | -4.6 | -2.6
During adjuvant treatment with exemestane, women with osteoporosis or at risk of osteoporosis should have their bone mineral density formally assessed by bone densitometry at the commencement of treatment. Monitor patients for bone mineral density loss and treat as appropriate.
Routine assessment of 25-hydroxy vitamin D levels prior to the start of aromatase inhibitor treatment should be performed, due to the high prevalence of vitamin D deficiency in women with early breast cancer (EBC). Women with vitamin D deficiency should receive supplementation with vitamin D.
Exemestane tablets should not be coadministered with systemic estrogen-containing agents as these could interfere with its pharmacologic action.
In patients with early breast cancer, the incidence of hematological abnormalities of Common Toxicity Criteria (CTC) grade ≥1 was lower in the exemestane treatment group, compared with tamoxifen. Incidence of CTC grade 3 or 4 abnormalities was low (approximately 0.1%) in both treatment groups. Approximately 20% of patients receiving exemestane in clinical studies in advanced breast cancer experienced CTC grade 3 or 4 lymphocytopenia. Of these patients, 89% had a pre-existing lower grade lymphopenia. …
Exemestane side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Reductions in Bone Mineral Density (BMD)
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Adjuvant Therapy
The data described below reflect exposure to exemestane in 2325 postmenopausal women with early breast cancer. Exemestane tolerability in postmenopausal women with early breast cancer was evaluated in two well-controlled trials: the IES study
and the 027 study (a randomized, placebo-controlled, double-blind, parallel group study specifically designed to assess the effects of exemestane on bone metabolism, hormones, lipids, and coagulation factors over 2 years of treatment).
The median duration of adjuvant treatment was 27.4 months and 27.3 months for patients receiving exemestane or tamoxifen, respectively, within the IES study and 23.9 months for patients receiving exemestane or placebo within the 027 study. Median duration of observation after randomization for exemestane was 34.5 months and for tamoxifen was 34.6 months. Median duration of observation was 30 months for both groups in the 027 study. …
Drug interactions
Drugs That Induce CYP 3A4
Co-medications that induce CYP 3A4 (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, or St. John’s wort) may
significantly decrease exposure to exemestane. Dose modification is recommended for patients who are also receiving a
strong CYP 3A4 inducer
.
About this medicine
Exemestane tablets for oral administration contain 25 mg of exemestane, an irreversible, steroidal aromatase inactivator. Exemestane is chemically described as 6-methylenandrosta-1,4-diene-3,17-dione. Its molecular formula is C
20H
24O
2 and its structural formula is as follows:
The active ingredient is a white to slightly yellow powder with a molecular weight of 296.41. Exemestane is freely soluble in tetrahydrofuran and dimethylformamide; soluble in acetone, acetonitrile, methanol, and ethyl acetate; sparingly soluble in ethanol; very slightly soluble in n-hexane and insoluble in water.
Each exemestane tablet contains the following inactive ingredients: copovidone, crospovidone, hypromellose, magnesium stearate, mannitol, polyethylene glycol 400, silicified microcrystalline cellulose, sodium starch glycolate, and titanium dioxide.
How it works: Breast cancer cell growth may be estrogen-dependent. Aromatase is the principal enzyme that converts androgens to estrogens both in pre- and postmenopausal women. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 392b5b4f-3fb4-4ba7-a15a-6022298db719. Read the full official label on DailyMed.
Related medicines
Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone